Intestinibacter bartlettii

Information

Microbe Identification

Intestinibacter bartlettii

Microbe id: PMDBM2020776
Level: Species
NCBI Taxonomy ID:
Taxonomy Species: Intestinibacter bartlettii [261299]
Taxonomy Genus: Intestinibacter [1505657]
Taxonomy Family: Peptostreptococcaceae [186804]

Interactions between microbe and active substances


ⓘ How do we work out MGCs and BGCs of one specific species?


Metabolic gene clusters of Intestinibacter bartlettii

Identified MGC Region
(click for details)
MGC Cluster (Most Similar) Similarity Compound metabolized by the MGC Type of MGC Reference(PubMed ID)
Unclassified gene clusterArginineArginine to putrescinePMID: 30183487
Unclassified gene clustern.a.Others HGD unassignedPMID: 36782070
PorA C. sporogenesAromatic amino acids / proline / glutamate / leucine / histidine / arginine / n.a. / choline/proline/tryptophan/Tyr/Phe/leucine/valineOD AA metabolism,Others HGD unassigned,porAPMID: 29168502 / PMID: 20937090 / PMID: 27994578 / PMID: 15654892 / PMID: 22933560 / PMID: 30183487 / PMID: 36782070 / PMID: 31831639
Acetyl-CoA pathway C. beijerinckiiPyruvate / chemolithoautotrophic substrates such as CO and carbon dioxidePyruvate to acetate-formate,Acetyl-CoA pathwayPMID: 20622067 / PMID: 27733845
Rnf complex C. sporogenesEnergy-capturing-relatedRnf complexPMID: 23269825
PFOR II pathway B. thetaiotaomicronGlycerol / ethanolamine / pyruvateOD eut pdu related,PFOR II pathwayPMID: 27242734 / PMID: 20234377 / PMID: 32301184
Gallic acid degradation B. sp. KLEGallic acidGallic acid metPMID: 30054365

n.s. indicates that no significant matches were found by KnownClusterBlast.

View gutSMASH Detailed Result
Biosynthetic gene clusters of Intestinibacter bartlettii


Identified BGC Region
(click for details)
BGC Cluster (Most Similar) Similarity Compound Synthesized by the BGC Type of BGC Reference (PubMed ID)
Unclassified gene clustern.a.RRE-containingPMID: 34019648
Unclassified gene clustern.a.RanthipeptidePMID: 34019648
ExopolysaccharideExopolysaccharideRRE-containingPMID: 17142402

n.s. indicates that no significant matches were found by KnownClusterBlast.

View antiSMASH Detailed Result
Map of Intestinibacter bartlettii distribution in human body and influence of diseases distribution in human body and influence of diseases


ⓘ How do you use the microbe distribution map?
ⓘ How did we get the relative abundance and microbe change in the map?
bodymap Oral Nose Esophagus Stomach Trachea Upper respiratory tract Vagina Blood Urethral Lung Cervix Rectum Skin Duodenum Fallopian tube Fallopian tube Peritoneal fluid Uterus Ear Ovary Ovary Colon Ileum Cecum
Disease id Bodysite Relative abundance (%) Disease name Microbe_change

Relative abundance landscape of Intestinibacter bartlettii in human gut microbiota samples



Abundance lanscape in healthy samples (by patients' age)
Abundance lanscape in healthy samples (by patients' country)
Abundance lanscape in disease samples
⚠ About the relative abundance profile

The relative taxonomical abundance data (pre-processed using a unified analysis pipeline) was retrieved from curatedMetagenomicData resource [Edoardo Pasolli, et al. Nat Methods. 2017;14(11):1023-1024]. Data retrieved here was pre-processed as unified relative abundance: at each taxonomic level (e.g., species, genus, family), the sum of microbial abundance of individual microbiota sample was 1, and relative abundance of each microbe was log10 transformed [relative abundance ranges from -7 to 0].

Healthy samples and disease samples (only disease types with >= 20 samples were included) were grouped by age periods, patients?country, or disease type to plot the relative abundance landscape using ggplot2 R package.



Comparative analysis of human gut metagenomes between disease and healthy samples of Intestinibacter bartlettii

Data source: Phenotype comparisons were obtained from GMrepo . We summarized all comparisons that included healthy samples as controls and overlapped with microbes represented in MASI.

Note: LDA scores below 0 indicate taxa enriched in healthy samples, whereas scores above 0 indicate taxa enriched in disease samples.

Disease Project ID LDA score Experiment Type
Kidney Failure, Chronic PRJNA449784🔗-3.02416890057366mNGS
Kidney Failure, Chronic PRJNA449784🔗-3.02180077000343mNGS
Hypertension PRJNA509999🔗-2.41251446259492mNGS
Hypertension PRJNA509999🔗-2.3851071168894mNGS
Diabetes Mellitus, Type 2 PRJNA871997🔗-3.9379324041095416S
Diabetes Mellitus, Type 2 PRJNA646010🔗-3.2884955088826316S
Diabetes Mellitus, Type 2 PRJDB5860🔗3.8300052766102216S
Diarrhea PRJEB14038🔗-2.09251112971123mNGS
Diarrhea PRJEB14038🔗-2.00046653197126mNGS
Colorectal Neoplasms PRJNA936589🔗-4.23001500729546mNGS
Colorectal Neoplasms PRJNA936589🔗-4.22519180141103mNGS
Colorectal Neoplasms PRJNA284542🔗-3.9266836156128416S
Colorectal Neoplasms PRJEB53415🔗3.0533365940968316S
Diabetes Mellitus, Type 1 PRJNA893406🔗-2.64883291565326mNGS
Diabetes Mellitus, Type 1 PRJNA893406🔗-2.5328093075323mNGS
Mental Disorders PRJNA278793🔗-3.0681484416247316S
Colitis, Ulcerative PRJNA983946🔗2.03562712533495mNGS
Colitis, Ulcerative PRJNA983946🔗2.14089406661909mNGS
Colitis, Ulcerative PRJNA993675🔗2.5724237766116mNGS
Colitis, Ulcerative PRJNA993675🔗2.60767227288641mNGS
Colitis, Ulcerative PRJEB76677🔗2.6594552059941mNGS
Colitis, Ulcerative PRJNA813736🔗2.83686068468929mNGS
Colitis, Ulcerative PRJNA813736🔗2.87971345248499mNGS
Spinal Cord Injuries PRJNA861246🔗-4.0211356693457416S
Carcinoma, Renal Cell PRJNA842560🔗2.9181474645226416S
Helicobacter Infections PRJDB10599🔗-3.5367853568410916S
Caliciviridae Infections PRJNA788674🔗-3.7347714638815516S
Non-alcoholic Fatty Liver Disease PRJNA851946🔗-3.9199750096212816S
Prostatic Neoplasms PRJNA762994🔗-3.4049442384512316S
Asthma PRJEB59709🔗2.7717502615056mNGS
Asthma PRJEB59709🔗2.89809566001839mNGS
Crohn Disease PRJNA993675🔗2.71888213804947mNGS
Crohn Disease PRJNA993675🔗2.74558186809633mNGS
Schistosomiasis haematobia PRJNA526732🔗-4.4605309361639616S
Purpura, Thrombocytopenic, Idiopathic PRJNA858062🔗-2.41914006974968mNGS
Purpura, Thrombocytopenic, Idiopathic PRJNA858062🔗-2.3567875273597mNGS
Cholestasis PRJNA478781🔗-3.4866773942471916S
Anorexia PRJNA674716🔗-2.96591542596808mNGS
Anorexia PRJNA674716🔗-2.9571262691884mNGS
Anorexia Nervosa PRJEB11199🔗3.0949617389942816S
Hepatitis C PRJNA1070593🔗-3.8432607767775516S
Hematologic Neoplasms PRJNA777832🔗-3.9131505854080116S
Myasthenia Gravis PRJNA688881🔗-2.45409058315253mNGS
Myasthenia Gravis PRJNA688881🔗-2.41902649081898mNGS
Irritable Bowel Syndrome PRJNA682378🔗-3.039236104623116S
Peutz-Jeghers Syndrome PRJNA905444🔗-3.2011671234194mNGS
Peutz-Jeghers Syndrome PRJNA905444🔗-3.18267274611632mNGS
Peutz-Jeghers Syndrome PRJNA545597🔗-2.6719037952881716S
Depressive Disorder, Major PRJNA762199🔗-2.71896227741608mNGS
Depressive Disorder, Major PRJNA762199🔗-2.6471196272679mNGS
Schistosomiasis japonica PRJNA625383🔗3.8608867047186616S
Alzheimer Disease PRJEB51982🔗-3.8398033285001216S
Liver Cirrhosis PRJNA861246🔗-4.0716165835270116S
Cystic Fibrosis PRJNA314903🔗-2.786416451903mNGS
Cystic Fibrosis PRJNA314903🔗-2.77558724531422mNGS
Obesity PRJNA1125836🔗3.27097727311345mNGS
Obesity PRJNA1125836🔗3.32125687794064mNGS
Diabetes Mellitus PRJNA400325🔗-3.7980213921461616S
Autism Spectrum Disorder PRJNA917543🔗-2.8886598411211516S
Inflammatory Bowel Diseases PRJEB13266🔗3.1565409736650416S
Biliary Atresia PRJNA730640🔗-2.28078030575758mNGS
Biliary Atresia PRJNA730640🔗-2.23978828549419mNGS
Multiple Sclerosis PRJEB28543🔗2.8680357224515mNGS
Multiple Sclerosis PRJEB28543🔗2.89716507343411mNGS
Multiple Sclerosis PRJEB53481🔗3.774938372485616S
Fibromyalgia PRJEB80379🔗-3.35830456369922mNGS
Fibromyalgia PRJEB80379🔗-3.31959472502014mNGS
COVID-19 PRJNA769052🔗-3.4761478867146216S
COVID-19 PRJNA678695🔗-3.222206439339216S
Sepsis PRJNA641414🔗2.6110145606685416S

Microbe-Therapeutic Substance associations are summarized based on THREE types of association evidence, these include:

Association of microbe alteration of therapeutic substances; Microbe and a specific substance will be associated when the microbe can metabolize the substance.
Association of therapeutic substance alteration of microbes; Microbe and a specific substance will be associated when the substance can make the abundance of a microbe increase or decrease.
Association of metabolic reactions of microbes (newly updated in MASI v2.0); This part of data came from microbe metabolic reconstructions based on genome via AGORA2 [Ref: Nature Biotechnology, 41 (2023) 1320?331]. A microbe and a specific substance will be associated when the microbe carries a specific gene whose product can metabolize the substance.





Therapeutic substance that metabolized by Intestinibacter bartlettii



Microbe Name Substance Name Substance Category Substance Subcategory Metabolism Type Metabolites Effects on Substance Experimental System Experimental Organism Experimental Disease Condition Alteration Mechanism Alteration Outcome Reference (PubMed ID)




Therapeutic Substances that affect the Intestinibacter bartlettii



Microbe Name Substance Name Substance Category Substance Subcategory Substance Details Effect on Microbe Effect Strength Experimental System Experimental Organism Experimental Disease Condition Reference (PubMed ID)


Drug involved metabolizing or transporting reactions that are carried out by Intestinibacter bartlettii

ⓘ How do we get these drug reactions?

To obtain the reactions associated with therapeutic substances, we followed a multi-step process:
Downloading Reconstructions: We started by downloading microbial genome-scale metabolic reconstructions from the AGORA2 [Ref: Nature Biotechnology, 41 (2023) 1320?331] database.
Identifying Drug-Associated Reactions: Next, we extracted all reactions that are linked to therapeutic substances from these reconstructions. This involved filtering and identifying reactions specifically related to drug metabolism and transport.
Linking Reaction to Microbes: Utilizing the identified reaction related genes (UidA, Tdc etc.), we machted the corresponding drug-associated reactions to existing microbes in the reconstructions in AGORA2. We could link the presence of these genes in different microbes to the potential for those microbes to carry out the corresponding drug-related reactions.
Putative Drug Reactions: As a result, the drug reactions identified in this manner are putative, meaning they are inferred based on the presence of specific gene sequences. This provides a hypothetical but informed prediction of the microbial capability to interact with therapeutic substances.



Statistical Charts
Detailed Information in Table
Original GEM Files (AGORA2)

Classification of Metabolizing or Transporting Related Reactions

Pie Chart of Functionally Related Protein Families

We provide links to the Genomic-Scale Metabolic Models (GEMs) used in this part, sourced from AGORA2, allowing access to the original .mat files. For more details, visit the AGORA2 repository.

# Model Download
1Intestinibacter_bartlettii_ERR1022395 Download
2Intestinibacter_bartlettii_ERR1022418 Download

Detailed Information of drug reactions

Metabolism
Transport
Drug Substrate Drug Metabolite Gene responsible for the reaction Reaction Description Reaction Formula Reaction Subsystem Subsystem Class type Subsystem Class level 1 Subsystem Class level 2 Subsystem Class level 3 Reference (PubMed ID) Microbe Name
Substance Name Gene responsible for the reaction Reaction Description Reaction Subsystem Subsystem Class type Subsystem Class level 1 Subsystem Class level 2 Subsystem Class level 3 Reference (PubMed ID) Microbe Name




Microbe-Herbal Substance associations are summarized based on TWO types of association evidence, these include:

Association of microbe alteration of herbal substances; Microbe and a specific substance will be associated when the microbe can metabolize the substance.
Association of herbal substance alteration of microbes; Microbe and a specific substance will be associated when the substance can make the abundance of a microbe increase or decrease.





Traditional medicines/herbs/herbal compounds that metabolized by Intestinibacter bartlettii


Microbe Name Substance Name Substance Category Substance Subcategory Metabolism Type Metabolites Effects on Substance Experimental System Experimental Organism Experimental Disease Condition Alteration Mechanism Alteration Outcome Reference (PubMed ID)




Traditional medicines/herbs/herbal compounds that affect the Intestinibacter bartlettii



Microbe Name Substance Name Substance Category Substance Subcategory Substance Details Effect on Microbe Effect Strength Experimental System Experimental Organism Experimental Disease Condition Reference (PubMed ID)

Microbe-Dietary Substance associations are summarized based on THREE types of association evidence, these include:

Association of microbe alteration of dietary substances; Microbe and a specific substance will be associated when the microbe can metabolize the substance.
Association of dietary substance alteration of microbes; Microbe and a specific substance will be associated when the substance can make the abundance of a microbe increase or decrease.
Association of metabolic reactions of microbes (newly updated in MASI v2.0); This part of data came from microbe metabolic reconstructions based on genome via AGREDA [Ref:Nature Communications, 12 (2021) 4728]. A microbe and a specific substance will be associated when the microbe carries a specific gene whose product can metabolize the substance.





Dietary Substances alter the abundance of Intestinibacter bartlettii

Microbe Name Substance Name Substance Category Substance Subcategory Substance Details Effect on Microbe Effect Strength Experimental System Experimental Organism Experimental Disease Condition Reference (PubMed ID)





Dietary substance that metabolized by Intestinibacter bartlettii

Microbe Name Substance Name Substance Category Substance Subcategory Substance Details Effect on Microbe Effect Strength Experimental System Experimental Organism Experimental Disease Condition Reference (PubMed ID)




Dietary Substance involved metabolizing or transporting reactions that are carried out by Intestinibacter bartlettii

ⓘ How do we get these diet reactions?

To obtain the reactions associated with dietary substances, we followed a multi-step process:
Downloading Reconstructions: We started by downloading microbial genome-scale metabolic reconstructions from the AGREDA [Ref:Nature Communications, 12 (2021) 4728] database.
Identifying Diet-Associated Reactions: Next, we extracted all reactions that are linked to dietary substances from these reconstructions. This involved filtering and identifying reactions specifically related to dietary substance metabolism and transport.
Linking Reactions to Microbes: Using the identified related genes (e.g., UidA, Tdc) for each drug metabolite reaction, we matched these reactions to microbes possessing the corresponding genes. This allowed us to link the presence of these genes in different microbes to their potential for carrying out the associated drug-related reactions.
Putative Drug Reactions: As a result, the diet reactions identified in this manner are putative, meaning they are inferred based on the presence of specific gene sequences. This provides a hypothetical but informed prediction of the microbial capability to interact with dietary substances.



Statistical Charts
Detailed Information in Table
Original GEM Files (AGREDA)

Classification of Metabolizing or Transporting Related Reactions

Pie Chart of Functionally Related Protein Families

We provide links to the Genomic-Scale Metabolic Models (GEMs) used in this part, sourced from AGREDA, allowing access to the original .xml files. For more details, visit the AGREDA repository.

# Model View
No records found!

Detailed Information of diet reactions

Metabolism
Transport
Diet Substrate Enzyme Reaction Formula Reaction Subsystem Subsystem Class type Subsystem Class level 1 Subsystem Class level 2 Subsystem Class level 3 Reference (PubMed ID) Microbe Name
Dietary Substance Name Reaction Name Reaction Subsystem Subsystem Class type Subsystem Class level 1 Subsystem Class level 2 Subsystem Class level 3 Reference (PubMed ID) Microbe Name




Microbe-Environmental Substance associations are summarized based on TWO types of association evidence, these include:

Association of microbe alteration of environmental substances; Microbe and a specific substance will be associated when the microbe can metabolize the substance.
Association of environmental substance alteration of microbes; Microbe and a specific substance will be associated when the substance can make the abundance of a microbe increase or decrease.





Environmental Substances that metabolized by Intestinibacter bartlettii



Microbe Name Substance Name Substance Category Substance Subcategory Metabolism Type Metabolites Effects on Substance Experimental System Experimental Organism Experimental Disease Condition Alteration Mechanism Alteration Outcome Reference (PubMed ID)




Environmental Substances that affect the Intestinibacter bartlettii


Microbe Name Substance Name Substance Category Substance Subcategory Substance Details Effect on Microbe Effect Strength Experimental System Experimental Organism Experimental Disease Condition Reference (PubMed ID)
ⓘ Background And User Guideline

Microbe Taxonomy level Species Quorum Sensing (QS) Language QS Language Class Total No. of QS Languages of the Species Reference (PubMed ID)


Diseases associated with the microbe Intestinibacter bartlettii


No data available

Microbiota Site Disease Name Disease Association Class Disease Associated Abundence Change Reference (PubMed ID)



Landscape of Bacteria-Substance-Disease Interaction/Association Network



ⓘ How is the network built?